CIK 0001438533
- Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- Operating
- EIN
- 262383102
- Phone
- +1 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,495,607
- in 10 filings, $79.5M under 10b5-1 plans
Net −$79,495,607. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 20 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-15 | Inrig Jula EVP, Head of R&D & CMO | Exercise or conversion 10b5-1 | +32,395 | $8.93 | $289K | 145,165 |
| 2026-09-15 | Inrig Jula EVP, Head of R&D & CMO | Sale 10b5-1 | −25,390 | $62.02 | $1.6M | 119,775 |
| 2026-09-15 | Inrig Jula EVP, Head of R&D & CMO | Sale 10b5-1 | −17,284 | $62.62 | $1.1M | 102,491 |
| 2026-09-15 | Inrig Jula EVP, Head of R&D & CMO | Sale 10b5-1 | −1,600 | $63.69 | $102K | 100,891 |
| 2026-09-15 | Inrig Jula EVP, Head of R&D & CMO | Sale 10b5-1 | −400 | $65.31 | $26K | 100,491 |
| 2026-09-15 | Inrig Jula EVP, Head of R&D & CMO | Exercise or conversion · Employee stock option (right to buy) 10b5-1 | −32,395 | 43,605 | ||
| 2026-06-22 | Inrig Jula CHIEF MEDICAL OFFICER | Gift | −468 | 112,770 | ||
| 2026-05-06 | Inrig Jula CHIEF MEDICAL OFFICER | Sale 10b5-1 | −311 | $43.95 | $14K | 113,238 |
| 2026-05-05 | Inrig Jula CHIEF MEDICAL OFFICER | Sale 10b5-1 | −2,174 | $46.65 | $101K | 113,549 |
| 2026-05-04 | Inrig Jula CHIEF MEDICAL OFFICER | Exercise or conversion 10b5-1 | +20,000 | $22.40 | $448K | 131,473 |
| 2026-05-04 | Inrig Jula CHIEF MEDICAL OFFICER | Sale 10b5-1 | −20,000 | $45.00 | $900K | 111,473 |
| 2026-05-04 | Inrig Jula CHIEF MEDICAL OFFICER | Exercise or conversion 10b5-1 | +4,250 | 115,723 | ||
| 2026-05-04 | Inrig Jula CHIEF MEDICAL OFFICER | Exercise or conversion · Employee stock option (right to buy) 10b5-1 | −20,000 | 34,500 | ||
| 2026-05-04 | Inrig Jula CHIEF MEDICAL OFFICER | Grant or award · Performance-based restricted stock units 10b5-1 | +8,500 | 8,500 | ||
| 2026-05-04 | Inrig Jula CHIEF MEDICAL OFFICER | Exercise or conversion · Performance-based restricted stock units 10b5-1 | −4,250 | 4,250 | ||
| 2026-04-15 | Inrig Jula CHIEF MEDICAL OFFICER | Sale 10b5-1 | −1,018 | $42.61 | $43K | 111,473 |
| 2026-04-14 | Inrig Jula CHIEF MEDICAL OFFICER | Sale 10b5-1 | −7,215 | $41.93 | $303K | 112,491 |
| 2026-04-13 | Inrig Jula CHIEF MEDICAL OFFICER | Grant or award 10b5-1 | +14,000 | 119,706 | ||
| 2026-02-04 | Inrig Jula CHIEF MEDICAL OFFICER | Sale 10b5-1 | −1,547 | $32.11 | $50K | 105,938 |
| 2026-02-04 | Inrig Jula CHIEF MEDICAL OFFICER | Sale 10b5-1 | −232 | $32.85 | $8K | 105,706 |
Page 1 of 3 · 54 trades